The cornerstone of ORIEN® is the common Total Cancer Care® (TCC) protocol, a longitudinal and post-study surveillance study of cancer patients. ORIEN® is harnessing technology-based collaboration to break down barriers between institutions, enable rapid learning, and accelerate research and discovery efforts to bring new treatments to patients. To enable even greater collaboration with ORIEN®—for members and nonmembers alike—we offer a Project Submission feature. This gives scientists the opportunity to explore potential research collaborations utilizing the Network’s vast resources.
With 400,000 patients enrolled in the TCC® protocol to date, the TCC® protocol provides an opportunity to generate real-world data (RWD) for cancer patients undergoing treatment. RWD is health and treatment outcome-related information that is collected in real-world medical settings. This rich dataset may be utilized to generate insights, or real-world evidence (RWE) about a medication or treatment regimen effectiveness and safety in the real-world setting, outside of traditional controlled clinical trial environment.
The ORIEN AVATAR® program, which was launched in 2016, generates whole exome and transcriptome data for TCC-consented patients with high-risk cancers and links longitudinal clinical data throughout a patient’s lifetime. Through ORIEN®, network members collect and share clinical data and specimens for analysis to foster and enable translational research. Aster Insights has developed a network data model system to integrate data from multiple sources and institutions to support team science and address complex cancer research questions. The rich ORIEN® data enables deeper understanding of the cancer drug pharmacodynamics in patients and stimulates novel hypotheses for preclinical, translational and clinical research.
Enrollment of patients in the TCC® protocol offers patients increased probability of being matched to effective clinical trial. Additionally, the pace of clinical trial development can be accelerated by taking a proactive approach to rapidly identify eligible patients for the trial using the ORIEN Avatar® data. This approach improves clinical trial efficiency by reducing study timeline and overall costs. Centrally managed by Aster Insights, the OCTN provides the ability to identify patients for target-based clinical trials. In addition to the rapid patient identification process, OCTN further enhances trial efficiency through a centralized protocol review and approval process.
Aligning with the ORIEN® mission of accelerating cancer discovery and delivering hope through collaborative learning and partnerships, ORIEN® Intermember Projects encourage research opportunities between ORIEN® member institutions, and are inclusive of nonmember and industry partners. ORIEN® Intermember Projects provide a forum for clinical and scientific experts to exchange ideas and identify areas for collaboration to address unmet needs; advancing cancer research and patient care.
For more information about proposing a project or to discuss research opportunities in your area of interest, submit a project inquiry below or contact ORIENprojects@AsterInsights.com
Our ecosystem is scientifically rooted and believes meaningful advancements for patients come from data-driven decisions. See how we are already contributing to the fight against cancer. The following publications were developed by ORIEN® members based on Total Cancer Care® data.
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96. doi: 10.1016/j.ijrobp.2009.06.014. PMID: 19735873. https://www.ncbi.nlm.nih.gov/pubmed/?term=19735873
Cancer biomarkers--an invitation to the table. Dalton WS, Friend SH. Science. 2006 May 26;312(5777):1165-8. https://www.ncbi.nlm.nih.gov/pubmed/16728629